SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IDEX

IDEX is trending as the community anticipates potential news regarding a migration plan and increased volume, with many traders optimistic about a breakout as it recovers from recent volatility. Speculation remains high among holders who are comparing its setup to previous market runs while debating whether current price action signals a sustained rally or a temporary shift.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is currently trading in a volatile range as market participants closely monitor the high-stakes diplomatic negotiations between the U.S. and Iran over the Strait of Hormuz. While some investors view recent price action as a consolidation period ahead of potential clarity on the geopolitical conflict, the community remains deeply divided, with discussions oscillating between anticipation of a deal-driven rally and fears of a broader market correction.

NKN is building the largest blockchain for network sharing.

New Kind of Network

NKN is capturing significant attention as traders speculate on potential partnerships and market reversals, with many members of the community comparing its current movement to other recent low-cap surges. Discussions are heavily focused on the stock's potential for a short squeeze and long-term recovery, though some participants remain skeptical, labeling the volatility as manipulated.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is trending as investors digest its high-profile foundry partnerships and the recent expansion of its high-speed modulator platform into GlobalFoundries' design ecosystem. The community remains hyper-focused on the company's potential to solve AI-driven data bottlenecks, with active debates centered on the timeline for commercial volume production and the high volatility surrounding its speculative growth trajectory.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Holdings is trending as investors react to a high-profile contract to deploy counter-drone security for the 2026 FIFA World Cup, fueling excitement around the company's expanding role in defense and autonomous infrastructure. While the community is actively debating the implications of potential share dilution and ongoing geopolitical tensions, long-term investors remain focused on the firm's robust pipeline of government contracts and its strategic integration of AI-enabled surveillance technology.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is currently trending due to its emerging role as a key infrastructure layer for on-chain AI agents within the Base ecosystem. While the community remains sharply divided between short-term traders looking to scalp volatility and long-term believers highlighting the project's real revenue generation and ongoing developer updates, sentiment is heavily influenced by the potential for a major market cap revaluation.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is generating significant investor buzz as the company secures $24 billion in funding from Middle East sovereign wealth funds, fueling optimism about its ability to deleverage and finalize the Warner Bros. Discovery merger. Community discourse is heavily focused on the potential for a short squeeze given the high short interest, alongside active debates regarding the strategic value of newly issued warrants and the company's long-term pivot toward an AI-driven, tech-forward media model.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The S&P 500 ETF is currently experiencing intense volatility as market participants react to the collapse of high-stakes peace negotiations between the U.S. and Iran. The community is sharply divided, with traders debating whether to hedge against a broader conflict and potential energy supply shocks or to bet on a sudden market reversal following further political commentary.

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Assertio Holdings Inc

Assertio Holdings is currently under significant investor scrutiny as shareholders debate the merits of a potential cash tender offer from Garda Therapeutics, with many expressing frustration over the valuation relative to the company's cash reserves and core assets like Rolvedon. The community is actively discussing possible regulatory and legal avenues to oppose the deal, while concerns persist regarding management's transparency and potential conflicts of interest surrounding executive compensation and the timing of the acquisition.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disney is attracting significant market attention as it prepares for a leadership transition, with Josh D'Amaro set to take the helm as CEO amidst ongoing debates regarding the company's streaming profitability, park performance, and recent box office releases. Investors are closely monitoring the stock's technical levels and analyst sentiment as the community debates whether the companys current valuation offers a long-term turnaround opportunity or remains hindered by structural challenges.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Scholar Rock (NASDAQ:SRRK) Reaches New 52-Week High  - What's Next?

Scholar Rock (NASDAQ:SRRK) Hits New 52-Week High - Time to Buy...

SG Americas Securities LLC Has $3.72 Million Stock Position in Scholar Rock Holding Corporation $SRRK

SG Americas Securities LLC raised its stake in Scholar Rock Holding Corporation (NASDAQ:SRRK - Free Report) by 602.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 84,349 shares of the company's stock after buy...

SRRK Stock Jumps on Resubmission of FDA Filing for SMA Drug

Scholar Rock stock jumps 14% after it resubmits its FDA filing for SMA drug apitegromab, revives approval hopes and sets up a potential September 2026 decision.

Wedbush Forecasts Strong Price Appreciation for Scholar Rock (NASDAQ:SRRK) Stock

Wedbush raised their price objective on shares of Scholar Rock from $56.00 to $58.00 and gave the stock an "outperform" rating in a research report on Wednesday...

Scholar Rock (NASDAQ:SRRK) Sets New 12-Month High - Should You Buy?

Scholar Rock (NASDAQ:SRRK) Reaches New 12-Month High - Here's What Happened...

Scholar Rock Resubmits Apitegromab BLA for SMA, Adds Second Fill-Finish Site; FDA Decision Eyed by Sept.

Scholar Rock (NASDAQ:SRRK) said it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration for apitegromab as a treatment for children and adults with spinal...

<ul class="summary-bullets"><li>Raymond James raised the price target to $60 from $53, while maintaining a ‘Strong Buy’ rating, according to The Fly.</li><li>H.C. Wainwright called the resubmission a ‘material de-risking event.’</li><li>The FDA is expected to announce a potential decision by September 2026.</li></ul>Shares of Scholar Rock (SRRK) garnered significant retail attention on Tuesday after the pharmaceutical firm resubmitted its Biologics License Application with the U.S. Food and Drug Administration for a potential treatment of Spinal Muscular Atrophy.The resubmission follows earlier feedback tied to manufacturing inspections, rather than concerns about the drug itself. The treatment, Apitegromab, has shown meaningful improvements in motor function in late-stage trials.<a href="https://stocktwits.com/symbol/SRRK">SRRK’s shares</a> gained 12% to hit their highest levels since April 2021.<h2 class="st-heading-2">Raymond James Sees Strong Uptake</h2>Raymond James raised its price target on the stock to $60 from $53, while maintaining a ‘Strong Buy’ rating, according to The Fly. If approved, Apitegromab could see strong uptake, analyst Martin Auster said.H.C. Wainwright maintained its ‘Buy’ rating and the $58 price target. Analyst Andres Maldonado said the “chapter colored by regulatory setbacks is coming to a close for Scholar Rock as they move forward with strengthened FDA alignment, increased manufacturing redundancy, and clear commercial readiness.”The firm also sees the resubmission as a ‘material de-risking event’, improving the chances of approval and an early commercial rollout.<h2 class="st-heading-2">FDA’s Potential Decision By September</h2>The updated filing now includes manufacturing support from Catalent Indiana, along with a second U.S.-based fill-finish facility to strengthen supply. The FDA is expected to accept the application within 30 days, followed by a review period of up to six months, with a potential decision by September 2026.The therapy has already received multiple key designations from the FDA, including Fast Track, Orphan Drug, Priority Review, and Rare Pediatric Disease status. Meanwhile, the European Medicines Agency (EMA) has granted it both Priority Medicines (PRIME) and Orphan Medicinal Product designations.“As we execute our plans for both Catalent Indiana and our second fill-finish facility, we look forward to anticipated apitegromab approvals and launches in both the U.S. and Europe this year,” said David L. Hallal, Chairman and CEO of Scholar Rock.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits turned ‘bullish’ from ‘neutral’ a day earlier.One user said the company is highly likely to become an M&amp;A target.<stembedurl>https://stocktwits.com/Tdorsey1776/message/648608711</stembedurl>Year-to-date, the stock has gained around 10%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/polar-power-pola-stock-100dma-break/cZEP6NxRIVV">POLA Stock Finally Breaks 100-DMA After Four Attempts This Year – Retail Highlights Strong Potential Due To Data Center, Drone Exposure</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Scholar Rock Holding logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

SRRK Stock Surges To Near Five-Year Highs – Here’s Why Analysts Are Bullish About Its Latest FDA Filing

Scholar Rock shares jumped 12% after the company resubmitted its Biologics License Application with the FDA for its treatment of Spinal Muscular Atrophy.

Equity

Scholar Rock (NASDAQ:SRRK) Shares Gap Up - Here's Why

Scholar Rock (NASDAQ:SRRK) Shares Gap Up - Still a Buy...

Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance...

E. Ohman J or Asset Management AB Has $721,000 Stake in Scholar Rock Holding Corporation $SRRK

E. Ohman J or Asset Management AB cut its position in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK - Free Report) by 76.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,374 shares of the co...

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.80	--	--	N/A
Q4 '25	-$0.90	-$0.88	2.42%	BEAT
Q3 '25	-$0.84	-$0.90	-6.85%	MISSED
Q2 '25	-$0.66	-$0.98	-47.42%	MISSED
Q1 '25	-$0.66	-$0.67	-1.40%	MISSED

SRRK
Scholar Rock Holding Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest SRRK News

SRRKScholar Rock Holding Corp